118 results on '"Amler, S."'
Search Results
2. S301: GERMAN AMLCG-SURVIVORSHIP STUDY: QUALITY OF LIFE AND LIFE SATISFACTION IN AML LONG-TERM SURVIVORS
- Author
-
Telzerow, E., primary, Görlich, D., additional, Sauerland, C., additional, Moret, A. S., additional, Rothenberg-Thurley, M., additional, Mumm, F. H. A., additional, Amler, S., additional, Berdel, W. E., additional, Wörmann, B., additional, Krug, U., additional, Braess, J., additional, Heussner, P., additional, Hiddemann, W., additional, Spiekermann, K., additional, and Metzeler, K. H., additional
- Published
- 2022
- Full Text
- View/download PDF
3. Disinfection of transvaginal ultrasound probes in a clinical setting: comparative performance of automated and manual reprocessing methods
- Author
-
Buescher, D. L., Möllers, M., Falkenberg, M. K., Amler, S., Kipp, F., Burdach, J., Klockenbusch, W., and Schmitz, R.
- Published
- 2016
- Full Text
- View/download PDF
4. Influence of smoking on disease severity and antimalarial therapy in cutaneous lupus erythematosus: analysis of 1002 patients from the EUSCLE database
- Author
-
Kuhn, A., Sigges, J., Biazar, C., Ruland, V., Patsinakidis, N., Landmann, A., Amler, S., Bonsmann, G., Haust, M., Nyberg, F., Bata, Z., Mihályi, L., Olteanu, R., Pujol, R. M., Sánchez-Schmidt, J. M., Medenica, L., Skiljevic, D., Reich, A., Szepietowski, J. C., Dalle Vedove, C., Girolomoni, G., Hawro, T., Zalewska-Janowska, A., Glaeser, R., Huegel, R., Jedličková, H., Bygum, A., Laurinaviciene, R., Benoit, S., Broecker, E., Bahmer, F. A., Aberer, E., Wutte, N., Lipozencic, J., Marinovic, B., Sárdy, M., Bekou, V., Ruzicka, T., Frances, C., Soutou, B., Lee, H., Worm, M., Gruschke, A., Hunzelmann, N., Steinbrink, K., Romiti, R., Sticherling, M., Erfurt-Berge, C., Avgerinou, G., Papafragkaki, D., Antiga, E., Caproni, M., Mayer, B., Volc-Platzer, B., Kreuter, A., Tigges, C., Heil, P. M., and Stingl, G.
- Published
- 2014
- Full Text
- View/download PDF
5. High-Dose Chemotherapy and Blood Autologous Stem-Cell Rescue Compared With Standard Chemotherapy in Localized High-Risk Ewing Sarcoma: Results of Euro-E.W.I.N.G.99 and Ewing-2008
- Author
-
Whelan, J., Deley, M.C. le, Dirksen, U., Teuff, G. le, Brennan, B., Gaspar, N., Hawkins, D.S., Amler, S., Bauer, S., Bielack, S., Blay, J.Y., Burdach, S., Castex, M.P., Dilloo, D., Eggert, A., Gelderblom, H., Gentet, J.C., Hartmann, W., Hassenpflug, W.A., Hjorth, L., Jimenez, M., Klingebiel, T., Kontny, U., Kruseova, J., Ladenstein, R., Laurence, V., Lervat, C., Marec-Berard, P., Marreaud, S., Michon, J., Morland, B., Paulussen, M., Ranft, A., Reichardt, P., Berg, H. van den, Wheatley, K., Judson, I., Lewis, I., Craft, A., Juergens, H., Oberlin, O., Euro- E W I N G 99 Investigator, EWING-2008 Investigator, Paediatric Oncology, and CCA - Cancer Treatment and Quality of Life
- Subjects
0301 basic medicine ,Melphalan ,Cancer Research ,medicine.medical_specialty ,Vincristine ,medicine.medical_treatment ,Medizin ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Original Reports ,Medicine ,Etoposide ,Chemotherapy ,Ifosfamide ,business.industry ,Hazard ratio ,medicine.disease ,030104 developmental biology ,Oncology ,030220 oncology & carcinogenesis ,Sarcoma ,business ,Busulfan ,medicine.drug - Abstract
Purpose For over 30 years, the place of consolidation high-dose chemotherapy in Ewing sarcoma (ES) has been controversial. A randomized study was conducted to determine whether consolidation high-dose chemotherapy improved survival in patients with localized ES at high risk for relapse. Methods Randomization between busulfan and melphalan (BuMel) or standard chemotherapy (vincristine, dactinomycin, and ifosfamide [VAI], seven courses) was offered to patients if they were younger than 50 years of age with poor histologic response (≥ 10% viable cells) after receiving vincristine, ifosfamide, doxorubicin, and etoposide (six courses); or had a tumor volume at diagnosis ≥ 200 mL if unresected, or initially resected, or resected after radiotherapy. A 15% improvement in 3-year event-free survival (EFS) was sought (hazard ratio [HR], 0.60). Results Between 2000 and 2015, 240 patients classified as high risk (median age, 17.1 years) were randomly assigned to VAI (n = 118) or BuMel (n = 122). Seventy-eight percent entered the trial because of poor histologic response after chemotherapy alone. Median follow-up was 7.8 years. In an intent-to-treat analysis, the risk of event was significantly decreased by BuMel compared with VAI: HR, 0.64 (95% CI, 0.43 to 0.95; P = .026); 3- and 8-year EFS were, respectively, 69.0% (95% CI, 60.2% to 76.6%) versus 56.7% (95% CI, 47.6% to 65.4%) and 60.7% (95% CI, 51.1% to 69.6%) versus 47.1% (95% CI, 37.7% to 56.8%). Overall survival (OS) also favored BuMel: HR, 0.63 (95% CI, 0.41 to 0.95; P = .028); 3- and 8-year OS were, respectively, 78.0% (95% CI, 69.6% to 84.5%) versus 72.2% (95% CI, 63.3% to 79.6%) and 64.5% (95% CI, 54.4% to 73.5%) versus 55.6% (95% CI, 45.8% to 65.1%). Results were consistent in the sensitivity analysis. Two patients died as a result of BuMel-related toxicity, one after standard chemotherapy. Significantly more BuMel patients experienced severe acute toxicities from this course of chemotherapy compared with multiple VAI courses. Conclusion BuMel improved EFS and OS when given after vincristine, ifosfamide, doxorubicin, and etoposide induction in localized ES with predefined high-risk factors. For this group of patients, BuMel may be an important addition to the standard of care.
- Published
- 2018
- Full Text
- View/download PDF
6. Evaluation of disease activity and damage in different subtypes of cutaneous lupus erythematosus using the CLASI
- Author
-
Bein, D, Kuehn, E, Meuth, A M, Amler, S, Haust, M, Nyberg, F, Sauerland, C, Luger, T A, Bonsmann, G, and Kuhn, A
- Published
- 2011
- Full Text
- View/download PDF
7. Cross-reactive carbohydrate determinants strongly affect the results of the basophil activation test in hymenoptera-venom allergy
- Author
-
Mertens, M., Amler, S., Moerschbacher, B. M., and Brehler, R.
- Published
- 2010
- Full Text
- View/download PDF
8. Revised Cutaneous Lupus Erythematosus Disease Area and Severity Index (RCLASI): a modified outcome instrument for cutaneous lupus erythematosus
- Author
-
Kuhn, A., Amler, S., Beissert, S., Böhm, M., Brehler, R., Ehrchen, J., Grundmann, S., Haust, M., Ruland, V., Schiller, M., Schulz, P., Ständer, S., Sauerland, C., Luger, T. A., and Bonsmann, G.
- Published
- 2010
- Full Text
- View/download PDF
9. Lupus erythematosus tumidus is a separate subtype of cutaneous lupus erythematosus
- Author
-
Schmitt, V., Meuth, A. M., Amler, S., Kuehn, E., Haust, M., Messer, G., Bekou, V., Sauerland, C., Metze, D., Köpcke, W., Bonsmann, G., and Kuhn, A.
- Published
- 2010
- Full Text
- View/download PDF
10. Desinfektion transvaginaler Ultraschallsonden – Vergleich einer maschinellen Technik mittels UVC und einer Wischtuchdesinfektion im klinischen Alltag
- Author
-
Moellers, M, additional, Schmitz, J, additional, Schmitz, R, additional, Braun, J, additional, Amler, S, additional, Oelmeier de Murcia, K, additional, and Kossow, A, additional
- Published
- 2018
- Full Text
- View/download PDF
11. Prediction of Multiple Sclerosis after Childhood Isolated Optic Neuritis
- Author
-
U Grenzebach, Oliver Schwartz, Christiane Elpers, Amler S, Sven G. Meuth, Gerd Kurlemann, Barbara Fiedler, and T Allkemper
- Subjects
medicine.medical_specialty ,Disease onset ,medicine.diagnostic_test ,business.industry ,Medical record ,Multiple sclerosis ,Magnetic resonance imaging ,Neurological examination ,Visual evoked potentials ,medicine.disease ,Surgery ,Somatosensory evoked potential ,Internal medicine ,medicine ,Cardiology ,Optic neuritis ,business - Abstract
Isolated optic neuritis in adults (ON) is the most common initial manifestation of multiple sclerosis (MS). Conversion to MS after childhood ON is not well determined. We aimed to identify risk factors predicting MS following ON and to develop risk profiles with adjusted clinical follow-up based on current diagnostic tools. Medical records of 42 cases with isolated ON between 1970 and 2005 were analysed. In 2006 and 2007 all patients received a clinical follow-up investigation including ophthalmological and neurological examination, visual evoked potentials (VEPs), somatosensory evoked potentials (SEPs) and cerebral magnetic resonance imaging (cMRI). Investigation was performed to a mean follow-up of 18 years (3-38 years). 14% of all patients showed MS-like lesions in cMRI. Additional neurologic symptoms or abnormal cMRI at initial presentation indicating dissemination in space significantly altered the risk of MS (OR 16.0, 95% CI [1.5; 176.5], p = 0.020), (OR 4.6, 95% CI [0.7; 31.0], respectively). Severe visual loss and funduscopic affection reduced the likelihood for progression to MS (OR 0.2, 95% CI [0.0; 1.5]). Children presenting with isolated ON, neurological impairment at onset or especially coordinative dysfunction at follow-up and demyelinating lesions in cMRI at disease onset were at high risk for the development of MS.
- Published
- 2017
- Full Text
- View/download PDF
12. Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia
- Author
-
Rothenberg-Thurley, M, primary, Amler, S, additional, Goerlich, D, additional, Köhnke, T, additional, Konstandin, N P, additional, Schneider, S, additional, Sauerland, M C, additional, Herold, T, additional, Hubmann, M, additional, Ksienzyk, B, additional, Zellmeier, E, additional, Bohlander, S K, additional, Subklewe, M, additional, Faldum, A, additional, Hiddemann, W, additional, Braess, J, additional, Spiekermann, K, additional, and Metzeler, K H, additional
- Published
- 2017
- Full Text
- View/download PDF
13. Cutaneous lupus erythematosus: First multicenter database analysis of 1002 patients from the European Society of Cutaneous Lupus Erythematosus (EUSCLE)
- Author
-
Biazar, C. Sigges, J. Patsinakidis, N. Ruland, V. Amler, S. Bonsmann, G. Kuhn, A. Haust, M. Nyberg, F. Bata, Z. Mihályi, L. Olteanu, R. Pujol, R.M. Sánchez-Schmidt, J.M. Medenica, L. Skiljevic, D. Reich, A. Szepietowski, J.C. Dalle Vedove, C. Girolomoni, G. Hawro, T. Zalewska-Janowska, A. Glaeser, R. Huegel, R. Jedlicková, H. Bygum, A. Laurinaviciene, R. Benoit, S. Broecker, E. Bahmer, F.A. Aberer, E. Wutte, N. Lipozencic, J. Marinovic, B. Sárdy, M. Bekou, V. Ruzicka, T. Frances, C. Soutou, B. Lee, H. Worm, M. Gruschke, A. Hunzelmann, N. Steinbrink, K. Romiti, R. Sticherling, M. Erfurt-Berge, C. Avgerinou, G. Papafragkaki, D. Antiga, E. Caproni, M. Mayer, B. Volc-Platzer, B. Kreuter, A. Tigges, C. Heil, P.M. Stingl, G.
- Subjects
fungi - Abstract
In this prospective, cross-sectional, multicenter study, we assessed clinical and laboratory characteristics from patients with cutaneous lupus erythematosus (CLE) using the Core Set Questionnaire of the European Society of Cutaneous Lupus Erythematosus (EUSCLE). 1002 (768 females, 234 males) patients with different subtypes of CLE, such as acute CLE (ACLE, 304 patients), subacute CLE (SCLE, 236 patients), chronic CLE (CCLE, 397 patients), and intermittent CLE (ICLE, 65 patients), from 13 European countries were collected and statistically analyzed by an SPSS database. The main outcome measures included gender, age at onset of disease, LE-specific and LE-nonspecific skin lesions, photosensitivity, laboratory features, and the criteria of the American College of Rheumatology (ACR) for the classification of systemic lupus erythematosus. The mean age at onset of disease was 43.0±15.7 years and differed significantly between the CLE subtypes. In 347 (34.6%) of the 1002 patients, two or more CLE subtypes were diagnosed during the course of the disease and 453 (45.2%) presented with LE-nonspecific manifestations. Drug-induced CLE and SjögrenD́s Syndrome had the highest prevalence in SCLE patients (13.1% and 14.0%, respectively). Photosensitivity was significantly more frequent in patients with ACLE, SCLE, and ICLE compared with those with CCLE. The detection of antinuclear antibodies such as anti-Ro/SSA and anti-La/SSB antibodies revealed further significant differences between the CLE subtypes. In summary, the EUSCLE Core Set Questionnaire and its database facilitate the analysis of clinical and laboratory features in a high number of patients with CLE and will contribute to standardized assessment and monitoring of the disease in Europe. © 2012 Elsevier B.V.
- Published
- 2013
14. Importance of Transvaginal Elastography in the Diagnosis of Uterine Fibroids and Adenomyosis
- Author
-
Frank, M., additional, Schäfer, S., additional, Möllers, M., additional, Falkenberg, M., additional, Braun, J., additional, Möllmann, U., additional, Strube, F., additional, Fruscalzo, A., additional, Amler, S., additional, Klockenbusch, W., additional, and Schmitz, R., additional
- Published
- 2015
- Full Text
- View/download PDF
15. Diagnostik von uterinen Myomen mittels transvaginaler Elastografie
- Author
-
Frank, ML, primary, Schäfer, SD, additional, Möllers, M, additional, Falkenberg, MK, additional, Braun, J, additional, Möllmann, U, additional, Strube, F, additional, Fruscalzo, A, additional, Amler, S, additional, Klockenbusch, W, additional, and Schmitz, R, additional
- Published
- 2015
- Full Text
- View/download PDF
16. Desinfektion von vaginalen Ultraschallsonden im klinischen Alltag – maschinelle und manuelle Aufbereitungsmethoden im Vergleich
- Author
-
Büscher, DL, primary, Möllers, M, additional, Kipp, F, additional, Amler, S, additional, Burdach, J, additional, and Schmitz, R, additional
- Published
- 2014
- Full Text
- View/download PDF
17. Imaging of fetal thymus in pregnant women with rheumatic diseases
- Author
-
Warby, AC, primary, Amler, S, additional, Jacobi, AM, additional, Hammer, K, additional, Möllmann, U, additional, Falkenberg, MK, additional, Möllers, M, additional, Kiesel, L, additional, Klockenbusch, W, additional, and Schmitz, R, additional
- Published
- 2014
- Full Text
- View/download PDF
18. OP17.01: Disinfection of transvaginal ultrasound probes in a clinical setting; comparative performance of automated and manual reprocessing methods
- Author
-
Buescher, D.L., primary, Moellers, M., additional, Falkenberg, M.K., additional, Amler, S., additional, Burdach, J., additional, Klockenbusch, W., additional, and Schmitz, R., additional
- Published
- 2014
- Full Text
- View/download PDF
19. Cutaneous lupus erythematosus : First multicenter database analysis of 1002 patients from the European Society of Cutaneous Lupus Erythematosus (EUSCLE)
- Author
-
Biazar, C., Sigges, J., Patsinakidis, N., Ruland, V., Amler, S., Bonsmann, G., Kuhn, A., Haust, M., Nyberg, Filippa, Bata, Z., Mihályi, L., Olteanu, R., Pujol, R. M., Sánchez-Schmidt, J. M., Medenica, L., Skiljevic, D., Reich, A., Szepietowski, J. C., Dalle Vedove, C., Girolomoni, G., Hawro, T., Zalewska-Janowska, A., Glaeser, R., Huegel, R., Jedlicková, H., Bygum, A., Laurinaviciene, R., Benoit, S., Broecker, E., Bahmer, F. A., Aberer, E., Wutte, N., Lipozencic, J., Marinovic, B., Sárdy, M., Bekou, V., Ruzicka, T., Frances, C., Soutou, B., Lee, H., Worm, M., Gruschke, A., Hunzelmann, N., Steinbrink, K., Romiti, R., Sticherling, M., Erfurt-Berge, C., Avgerinou, G., Papafragkaki, D., Antiga, E., Caproni, M., Mayer, B., Volc-Platzer, B., Kreuter, A., Tigges, C., Heil, Peter Maximilian, Stingl, G., Biazar, C., Sigges, J., Patsinakidis, N., Ruland, V., Amler, S., Bonsmann, G., Kuhn, A., Haust, M., Nyberg, Filippa, Bata, Z., Mihályi, L., Olteanu, R., Pujol, R. M., Sánchez-Schmidt, J. M., Medenica, L., Skiljevic, D., Reich, A., Szepietowski, J. C., Dalle Vedove, C., Girolomoni, G., Hawro, T., Zalewska-Janowska, A., Glaeser, R., Huegel, R., Jedlicková, H., Bygum, A., Laurinaviciene, R., Benoit, S., Broecker, E., Bahmer, F. A., Aberer, E., Wutte, N., Lipozencic, J., Marinovic, B., Sárdy, M., Bekou, V., Ruzicka, T., Frances, C., Soutou, B., Lee, H., Worm, M., Gruschke, A., Hunzelmann, N., Steinbrink, K., Romiti, R., Sticherling, M., Erfurt-Berge, C., Avgerinou, G., Papafragkaki, D., Antiga, E., Caproni, M., Mayer, B., Volc-Platzer, B., Kreuter, A., Tigges, C., Heil, Peter Maximilian, and Stingl, G.
- Abstract
In this prospective, cross-sectional, multicenter study, we assessed clinical and laboratory characteristics from patients with cutaneous lupus erythematosus (CLE) using the Core Set Questionnaire of the European Society of Cutaneous Lupus Erythematosus (EUSCLE). 1002 (768 females, 234 males) patients with different subtypes of CLE, such as acute CLE (ACLE, 304 patients), subacute CLE (SCLE, 236 patients), chronic CLE (CCLE, 397 patients), and intermittent CLE (ICLE, 65 patients), from 13 European countries were collected and statistically analyzed by an SPSS database. The main outcome measures included gender, age at onset of disease, LE-specific and LE-nonspecific skin lesions, photosensitivity, laboratory features, and the criteria of the American College of Rheumatology (ACR) for the classification of systemic lupus erythematosus. The mean age at onset of disease was 43.0±15.7 years and differed significantly between the CLE subtypes. In 347 (34.6%) of the 1002 patients, two or more CLE subtypes were diagnosed during the course of the disease and 453 (45.2%) presented with LE-nonspecific manifestations. Drug-induced CLE and SjögrenD́s Syndrome had the highest prevalence in SCLE patients (13.1% and 14.0%, respectively). Photosensitivity was significantly more frequent in patients with ACLE, SCLE, and ICLE compared with those with CCLE. The detection of antinuclear antibodies such as anti-Ro/SSA and anti-La/SSB antibodies revealed further significant differences between the CLE subtypes. In summary, the EUSCLE Core Set Questionnaire and its database facilitate the analysis of clinical and laboratory features in a high number of patients with CLE and will contribute to standardized assessment and monitoring of the disease in Europe.
- Published
- 2013
- Full Text
- View/download PDF
20. Evaluation of disease activity and damage in different subtypes of cutaneous lupus erythematosus using the CLASI
- Author
-
Bein, D., Kuehn, E., Meuth, A. M., Amler, S., Haust, M., Nyberg, Fred, Sauerland, C., Luger, T. A., Bonsmann, G., Kuhn, A., Bein, D., Kuehn, E., Meuth, A. M., Amler, S., Haust, M., Nyberg, Fred, Sauerland, C., Luger, T. A., Bonsmann, G., and Kuhn, A.
- Abstract
Background: The Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) is a scoring system for patients with cutaneous lupus erythematosus (CLE) to assess disease activity and damage. Objective: The aim of this study was to evaluate whether the CLASI is a useful instrument which reflects the different subtypes of CLE comparably well in each parameter. Methods: A total of 50 patients (42 female, 8 male) with different subtypes of CLE, including acute CLE (ACLE), subacute CLE (SCLE), chronic CLE (CCLE) and LE tumidus (LET), from the Departments of Dermatology, University of Dusseldorf, Germany, and Danderyd Hospital, Stockholm, Sweden, were evaluated using the CLASI at one time point. Results: The total CLASI activity score was significantly lower in patients with LET compared with ACLE (P < 0.05) and CCLE (P < 0.001), and the total CLASI damage score was significantly lower in patients with LET than with ACLE (P < 0.05), SCLE (P < 0.001) and CCLE (P < 0.001). The erythema score and the scale/hypertrophy score were significantly lower in LET than in ACLE (P < 0.05, both) and CCLE (P < 0.05 and P < 0.001, respectively). The dyspigmentation score was lowest in patients with LET, differing significantly from ACLE (P < 0.05), SCLE (P < 0.05) and CCLE (P < 0.001). The scarring/atrophy/panniculitis score was significantly higher in patients with CCLE in contrast to SCLE and LET (P < 0.05 and P < 0.001, respectively). Conclusion: These data characterize the CLASI as an overall useful instrument to analyse disease activity and damage in CLE. However, the CLASI does not give an accurate assessment of all disease subtypes; therefore, a revision of the CLASI with critical analysis of all parameters is recommended.
- Published
- 2011
- Full Text
- View/download PDF
21. Langzeitergebnisse nach Tonsillotomie zur Behandlung schlafbezogener Atmungsstörungen bei Kindern
- Author
-
Deitmer, T, Eisfeld, W, Amler, S, Deitmer, T, Eisfeld, W, and Amler, S
- Published
- 2010
22. Imaging of fetal thymus in pregnant women with rheumatic diseases
- Author
-
Warby, AC, primary, Amler, S, additional, Jacobi, A, additional, Hammer, K, additional, Möllmann, U, additional, Falkenberg, M, additional, Möllers, M, additional, Klockenbusch, W, additional, and Schmitz, R, additional
- Published
- 2013
- Full Text
- View/download PDF
23. Importance of Transvaginal Elastography in the Diagnosis of Uterine Fibroids and Adenomyosis.
- Author
-
Frank, M. L., Schäfer, S. D., Möllers, M., Falkenberg, M. K., Braun, J., Möllmann, U., Strube, F., Fruscalzo, A., Amler, S., Klockenbusch, W., and Schmitz, R.
- Published
- 2016
- Full Text
- View/download PDF
24. Diagnose der Lungenembolie Sensitivität und Spezifität der D-Dimere und des Wells-Score in Abhängigkeit vom gewählten Cut-off-Wert und der Nierenfunktion
- Author
-
Sieling, S., primary, Amler, S., additional, Kisters, K., additional, and Hausberg, M., additional
- Published
- 2012
- Full Text
- View/download PDF
25. Experimental pathology
- Author
-
Yi Chun, D. X., primary, Alexandre, H., additional, Edith, B., additional, Nacera, O., additional, Julie, P., additional, Chantal, J., additional, Eric, R., additional, Zhang, X., additional, Jin, Y., additional, Miravete, M., additional, Dissard, R., additional, Klein, J., additional, Gonzalez, J., additional, Caubet, C., additional, Pecher, C., additional, Pipy, B., additional, Bascands, J.-L., additional, Mercier-Bonin, M., additional, Schanstra, J., additional, Buffin-Meyer, B., additional, Claire, R., additional, Rigothier, C., additional, Richard, D., additional, Sebastien, L., additional, Moin, S., additional, Chantal, B., additional, Christian, C., additional, Jean, R., additional, Migliori, M., additional, Cantaluppi, V., additional, Mannari, C., additional, Medica, D., additional, Giovannini, L., additional, Panichi, V., additional, Goldwich, A., additional, Alexander, S., additional, Andre, G., additional, Amann, K., additional, Migliorini, A., additional, Sagrinati, C., additional, Angelotti, M. L., additional, Mulay, S. R., additional, Ronconi, E., additional, Peired, A., additional, Romagnani, P., additional, Anders, H.-J., additional, Chiang, W. C., additional, Lai, C. F., additional, Peng, W.-H., additional, Wu, C. F., additional, Chang, F.-C., additional, Chen, Y.-T., additional, Lin, S.-L., additional, Chen, Y. M., additional, Wu, K. D., additional, Lu, K.-S., additional, Tsai, T. J., additional, Virgine, O., additional, Qing Feng, F., additional, Zhang, S.-Y., additional, Dominique, D., additional, Vincent, A., additional, Marina, C., additional, Philippe, L., additional, Georges, G., additional, Pawlak, A., additional, Sahali, D., additional, Matsumoto, S., additional, Kiyomoto, H., additional, Ichimura, A., additional, Dan, T., additional, Nakamichi, T., additional, Tsujita, T., additional, Akahori, K., additional, Ito, S., additional, Miyata, T., additional, Xie, S., additional, Zhang, B., additional, Shi, W., additional, Yang, Y., additional, Nagasu, H., additional, Satoh, M., additional, Kidokoro, K., additional, Nishi, Y., additional, Ihoriya, C., additional, Kadoya, H., additional, Sasaki, T., additional, Kashihara, N., additional, Wu, C.-F., additional, Chou, Y.-H., additional, Duffield, J., additional, Rocca, C., additional, Gregorini, M., additional, Corradetti, V., additional, Valsania, T., additional, Bedino, G., additional, Bosio, F., additional, Pattonieri, E. F., additional, Esposito, P., additional, Sepe, V., additional, Libetta, C., additional, Rampino, T., additional, Dal Canton, A., additional, Omori, H., additional, Kawada, N., additional, Inoue, K., additional, Ueda, Y., additional, Yamamoto, R., additional, Matsui, I., additional, Kaimori, J., additional, Takabatake, Y., additional, Moriyama, T., additional, Isaka, Y., additional, Rakugi, H., additional, Wasilewska, A., additional, Taranta-Janusz, K., additional, Deebek, W., additional, Kuroczycka-Saniutycz, E., additional, Lee, A. S., additional, Lee, J. E., additional, Jung, Y. J., additional, Kang, K. P., additional, Lee, S., additional, Kim, W., additional, Arfian, N., additional, Emoto, N., additional, Yagi, K., additional, Nakayama, K., additional, Hartopo, A. B., additional, Nugrahaningsih, D. A., additional, Yanagisawa, M., additional, Hirata, K.-I., additional, Munoz-Felix, J. M., additional, Lopez-Novoa, J. M., additional, Martinez-Salgado, C., additional, Oujo, B., additional, Arevalo, M., additional, Bernabeu, C., additional, Perez-Barriocanal, F., additional, Jesper, K., additional, Nathalie, V., additional, Pierre, G., additional, Yi Chun, D. X., additional, Iyoda, M., additional, Shibata, T., additional, Matsumoto, K., additional, Shindo-Hirai, Y., additional, Kuno, Y., additional, Wada, Y., additional, Akizawa, T., additional, Schwartz, I., additional, Schwartz, D., additional, Prot Bertoye, C., additional, Terryn, S., additional, Claver, J., additional, Beghdadi, W. B., additional, Monteiro, R., additional, Blank, U., additional, Devuyst, O., additional, Daugas, E., additional, Van Beneden, K., additional, Geers, C., additional, Pauwels, M., additional, Mannaerts, I., additional, Van den Branden, C., additional, Van Grunsven, L. A., additional, Seckin, I., additional, Pekpak, M., additional, Uzunalan, M., additional, Uruluer, B., additional, Kokturk, S., additional, Ozturk, Z., additional, Sonmez, H., additional, Yaprak, E., additional, Furuno, Y., additional, Tsutsui, M., additional, Morishita, T., additional, Shimokawa, H., additional, Otsuji, Y., additional, Yanagihara, N., additional, Kabashima, N., additional, Ryota, S., additional, Kanegae, K., additional, Miyamoto, T., additional, Nakamata, J., additional, Ishimatsu, N., additional, Tamura, M., additional, Nakagawa, T., additional, Ichikawa, K., additional, Miyamoto, M., additional, Takabayashi, D., additional, Yamazaki, H., additional, Kakeshita, K., additional, Koike, T., additional, Kagitani, S., additional, Tomoda, F., additional, Hamashima, T., additional, Ishii, Y., additional, Inoue, H., additional, Sasahara, M., additional, El Machhour, F., additional, Kerroch, M., additional, Mesnard, L., additional, Chatziantoniou, C., additional, Dussaule, J.-C., additional, Inui, K., additional, Sasai, F., additional, Maruta, Y., additional, Nishiwaki, H., additional, Kawashima, E., additional, Inoue, Y., additional, Yoshimura, A., additional, Musacchio, E., additional, Priante, G., additional, Valvason, C., additional, Sartori, L., additional, Baggio, B., additional, Kim, J. H., additional, Gross, O., additional, Diana, R., additional, Gry, D. H., additional, Asimal, B., additional, Johanna, T., additional, Imke, S.-E., additional, Lydia, W., additional, Gerhard-Anton, M., additional, Hassan, D., additional, Cano, J. L., additional, Griera, M., additional, Olmos, G., additional, Martin, P., additional, Cortes, M. A., additional, Lopez-Ongil, S., additional, Rodriguez-Puyol, D., additional, DE Frutos, S., additional, Gonzalez, M., additional, Luengo, A., additional, Rodriguez-Puyol, M., additional, Calleros, L., additional, Lupica, R., additional, Lacquaniti, A., additional, Donato, V., additional, Maggio, R., additional, Mastroeni, C., additional, Lucisano, S., additional, Cernaro, V., additional, Fazio, M. R., additional, Quartarone, A., additional, Buemi, M., additional, Kacik, M., additional, Goedicke, S., additional, Eggert, H., additional, Hoyer, J. D., additional, Wurm, S., additional, Steege, A., additional, Banas, M., additional, Kurtz, A., additional, Banas, B., additional, Lasagni, L., additional, Lazzeri, E., additional, Romoli, S., additional, Schaefer, I., additional, Teng, B., additional, Worthmann, K., additional, Haller, H., additional, Schiffer, M., additional, Prattichizzo, C., additional, Netti, G. S., additional, Rocchetti, M. T., additional, Cormio, L., additional, Carrieri, G., additional, Stallone, G., additional, Grandaliano, G., additional, Ranieri, E., additional, Gesualdo, L., additional, Kucher, A., additional, Smirnov, A., additional, Parastayeva, M., additional, Beresneva, O., additional, Kayukov, I., additional, Zubina, I., additional, Ivanova, G., additional, Abed, A., additional, Schlekenbach, L., additional, Foglia, B., additional, Kwak, B., additional, Chadjichristos, C., additional, Queisser, N., additional, Schupp, N., additional, Brand, S., additional, Himer, L., additional, Szebeni, B., additional, Sziksz, E., additional, Saijo, S., additional, Kis, E., additional, Prokai, A., additional, Banki, N. F., additional, Fekete, A., additional, Tulassay, T., additional, Vannay, A., additional, Hegner, B., additional, Schaub, T., additional, Lange, C., additional, Dragun, D., additional, Klinkhammer, B. M., additional, Rafael, K., additional, Monika, M., additional, Anna, M., additional, Van Roeyen, C., additional, Boor, P., additional, Eva Bettina, B., additional, Simon, O., additional, Esther, S., additional, Floege, J., additional, Kunter, U., additional, Janke, D., additional, Jankowski, J., additional, Hayashi, M., additional, Takamatsu, I., additional, Horimai, C., additional, Yoshida, T., additional, Seno DI Marco, G., additional, Koenig, M., additional, Stock, C., additional, Reiermann, S., additional, Amler, S., additional, Koehler, G., additional, Fobker, M., additional, Buck, F., additional, Pavenstaedt, H., additional, Lang, D., additional, Brand, M., additional, Plotnikov, E., additional, Morosanova, M., additional, Pevzner, I., additional, Zorova, L., additional, Pulkova, N., additional, Zorov, D., additional, Wornle, M., additional, Ribeiro, A., additional, Belling, F., additional, Merkle, M., additional, Nakazawa, D., additional, Nishio, S., additional, Shibasaki, S., additional, Tomaru, U., additional, Akihiro, I., additional, Kobayashi, I., additional, Imanishi, Y., additional, Kurajoh, M., additional, Nagata, Y., additional, Yamagata, M., additional, Emoto, M., additional, Michigami, T., additional, Ishimura, E., additional, Inaba, M., additional, Wu, C.-C., additional, Lu, K.-C., additional, Chen, J.-S., additional, Chu, P., additional, Lin, Y.-F., additional, Eller, K., additional, Schroll, A., additional, Kirsch, A., additional, Huber, J., additional, Weiss, G., additional, Theurl, I., additional, Rosenkranz, A. R., additional, Zawada, A., additional, Rogacev, K., additional, Achenbach, M., additional, Fliser, D., additional, Held, G., additional, Heine, G. H., additional, Miyamoto, Y., additional, Iwao, Y., additional, Watanabe, H., additional, Kadowaki, D., additional, Ishima, Y., additional, Chuang, V. T. G., additional, Sato, K., additional, Otagiri, M., additional, Maruyama, T., additional, Iwatani, H., additional, Honda, D., additional, Noguchi, T., additional, Tanaka, M., additional, Tanaka, H., additional, Fukagawa, M., additional, Pircher, J., additional, Koppel, S., additional, Mannell, H., additional, Krotz, F., additional, Virzi, G. M., additional, Bolin, C., additional, Cruz, D., additional, Scalzotto, E., additional, De Cal, M., additional, Vescovo, G., additional, Ronco, C., additional, Grobmayr, R., additional, Lech, M., additional, Ryu, M., additional, Aoshima, Y., additional, Mizobuchi, M., additional, Ogata, H., additional, Kumata, C., additional, Nakazawa, A., additional, Kondo, F., additional, Ono, N., additional, Koiwa, F., additional, Kinugasa, E., additional, Freisinger, W., additional, Lale, N., additional, Lampert, A., additional, Ditting, T., additional, Heinlein, S., additional, Schmieder, R. E., additional, Veelken, R., additional, Nave, H., additional, Perthel, R., additional, Suntharalingam, M., additional, Bode-Boger, S., additional, Beutel, G., additional, Kielstein, J., additional, Rodrigues-Diez, R., additional, Rayego-Mateos, S., additional, Lavoz, C., additional, Stark Aroeira, L. G., additional, Orejudo, M., additional, Alique, M., additional, Ortiz, A., additional, Egido, J., additional, Ruiz-Ortega, M., additional, Oskar, W., additional, Rusan, C., additional, Padberg, J.-S., additional, Wiesinger, A., additional, Reuter, S., additional, Grabner, A., additional, Kentrup, D., additional, Lukasz, A., additional, Oberleithner, H., additional, Pavenstadt, H., additional, Kumpers, P., additional, Eberhardt, H. U., additional, Skerka, C., additional, Chen, Q., additional, Hallstroem, T., additional, Hartmann, A., additional, Kemper, M. J., additional, Zipfel, P. F., additional, N'gome-Sendeyo, K., additional, Fan, Q.-F., additional, Toblli, J., additional, Cao, G., additional, Giani, J. F., additional, Dominici, F. P., additional, Kim, J. S., additional, Yang, J. W., additional, Kim, M. K., additional, Han, B. G., additional, and Choi, S. O., additional
- Published
- 2012
- Full Text
- View/download PDF
26. Calcineurin Inhibitor-free Immunosuppression Using Everolimus (Certican) after Heart Transplantation: 2 years' Follow-up from the University Hospital Münster
- Author
-
Stypmann, J., primary, Engelen, M.A., additional, Eckernkemper, S., additional, Amler, S., additional, Gunia, S., additional, Sindermann, J.R., additional, Rothenburger, M., additional, Rukosujew, A., additional, Drees, G., additional, and Welp, H.A., additional
- Published
- 2011
- Full Text
- View/download PDF
27. Evaluation of disease activity and damage in different subtypes of cutaneous lupus erythematosus using the CLASI
- Author
-
Bein, D, primary, Kuehn, E, additional, Meuth, AM, additional, Amler, S, additional, Haust, M, additional, Nyberg, F, additional, Sauerland, C, additional, Luger, TA, additional, Bonsmann, G, additional, and Kuhn, A, additional
- Published
- 2010
- Full Text
- View/download PDF
28. Langzeitergebnisse nach Tonsillotomie im Kindesalter
- Author
-
Eisfeld, W., primary, Amler, S., additional, and Deitmer, T., additional
- Published
- 2010
- Full Text
- View/download PDF
29. 50: Everolimus (Certican) after Heart Transplantation: 2 Years' Single Center Follow-Up in Calcineurin Inhibitor-Free Immunosuppression
- Author
-
Engelen, M.A., primary, Welp, H., additional, Sindermann, J.R., additional, Amler, S., additional, and Stypmann, J., additional
- Published
- 2010
- Full Text
- View/download PDF
30. A Database Analysis of Cutaneous Lupus Erythematosus with the EUSCLE Core Set Questionnaire
- Author
-
Meuth, AM, additional, Amler, S, additional, Haust, M, additional, Bein, D, additional, Sauerland, C, additional, Köpcke, W, additional, Bonsmann, G, additional, Nyberg, F, additional, and Kuhn, A, additional
- Published
- 2010
- Full Text
- View/download PDF
31. Lupus erythematosus tumidus is a separate subtype of cutaneous lupus erythematosus
- Author
-
Schmitt, V., primary, Meuth, A.M., additional, Amler, S., additional, Kuehn, E., additional, Haust, M., additional, Messer, G., additional, Bekou, V., additional, Sauerland, C., additional, Metze, D., additional, Köpcke, W., additional, Bonsmann, G., additional, and Kuhn, A., additional
- Published
- 2009
- Full Text
- View/download PDF
32. Estimation of Patient Accrual Rates in Clinical Trials Based on Routine Data from Hospital Information Systems
- Author
-
Amler, S., primary, Lange, M., primary, Gerß, J., primary, Breil, B., primary, Köpcke, W., primary, and Dugas, M., additional
- Published
- 2009
- Full Text
- View/download PDF
33. Estimation of Patient Accrual Rates in Clinical Trials Based on Routine Data from Hospital Information Systems.
- Author
-
Dugas, M., Amler, S., Lange, M., Gerß, J., Breil, B., and Köpcke, W.
- Subjects
HOSPITAL patients ,CLINICAL trials ,HOSPITAL records ,HOSPITAL care ,INFORMATION resources management ,CHI-squared test ,ONCOLOGY ,CARDIOLOGY - Abstract
The article presents a study which examines the accrual rates of patients in clinical trials based on the hospital information systems' (HIS) routine data. It states that the study employs a HIS data report to list the possible trial subjects, and a Chi-squared test to analyze the matching and non-matching proportions of patients. It mentions that the report illustrates two oncology and cardiology datasets which explain the elimination of duplicate persons and disease episodes. It concludes that the data is applicable to estimate the patient accrual rates.
- Published
- 2009
- Full Text
- View/download PDF
34. Pesticides.
- Author
-
Weiss B, Amler S, and Amler RW
- Abstract
Pesticides are a broad group of heterogeneous chemicals that have a significant public health benefit by increasing food production productivity and decreasing food-borne and vector-borne diseases. However, depending on the agent and the exposure, they may pose health risks. Because of their behavior, acute accidental toxic exposures occur more commonly in children. Because of the dietary habits and greater intake of foods per kilogram in children and because some infants are breastfed, there is also concern about the effects on them of low-level environmental exposures. In the absence of direct conclusive evidence, consistent and relevant observations have led some investigators to infer that chronic low-dose exposure to certain pesticides might pose a potential hazard to the health and development of infants and children. Other investigators have concluded that such inferences can be neither supported nor refuted at the present time. The pediatrician has a role to play in recognizing the symptoms of acute exposure and to be able to provide appropriate treatment. It is essential to study whether there are subtle neurologic effects that may result from low-level pesticide exposures in individual patients. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
35. Liquid mercury: a poisonous plaything.
- Author
-
Amler S
- Abstract
Faced with a child who has been exposed to mercury, would you recognize the signs and symptoms? Would you know what questions to ask, which lab tests to draw, and what treatment to initiate? Would you know what to advise parents about a mercury spill at home? [ABSTRACT FROM AUTHOR]
- Published
- 2002
36. AML PATIENTS AGED >= 75 YEARS ENROLLED INTO AMLCG TRIALS: DO GENETIC ALTERATIONS IMPACT CLINICAL OUTCOME IN VERY OLD, INTENSIVELY TREATED PATIENTS?
- Author
-
Prassek, V., Rothenberg-Thurley, M., Sauerland, M. C., Amler, S., Goerlich, D., Herold, T., Janke, H., Schneider, S., Subklewe, M., Krug, U., Faldum, A., Berdel, W. E., Woermann, B., Braess, J., Hiddemann, W., Spiekermann, K., and Klaus Metzeler
37. PERSISTENCE OF DRIVER MUTATIONS DURING COMPLETE REMISSION ASSOCIATES WITH SHORTER SURVIVAL AND CONTRIBUTES TO THE INFERIOR OUTCOMES OF ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA
- Author
-
Rothenberg-Thurley, M., Amler, S., Goerlich, D., Sauerland, M. C., Schneider, S., Konstandin, N. P., Schaaf, S., Batcha, Nazeer A. M., Braeundl, K., Ksienzyk, B., Zellmaier, E., Mansmann, U., Fiegl, M., Subklewe, M., Bohlander, S. K., Faldum, A., Hiddemann, W., Spiekermann, K., Braess, J., and Klaus Metzeler
38. Prediction of Primary Refractory Acute Myeloid Leukemia
- Author
-
Herold, Tobias, Jurinovic, V., Klaus Metzeler, Batcha, A. M. N., Bamopoulos, S. A., Rothenberg-Thurley, M., Ksienzyk, B., Hartmann, L., Greif, P. A., Phillippou-Massier, J., Krebs, S., Blum, H., Amler, S., Schneider, S., Konstandin, N., Sauerland, M. C., Berdel, W. E., Woermann, B. J., Subklewe, M., Fiegl, M., Bohlander, S. K., Braess, J., Hiddemann, W., Mansmann, U., and Spiekermann, K.
39. Factors influencing life satisfaction in acute myeloid leukemia survivors following allogeneic stem cell transplantation: a cross-sectional study
- Author
-
Amler, S. (Susanne), Sauerland, C. (Cristina), Deiters, C. (Christian), Büchner, T. (Thomas), Schumacher, A. (Andrea), and Universitäts- und Landesbibliothek Münster
- Subjects
Medicine and health ,Public Health, Environmental and Occupational Health ,ddc:610 ,Acute Myeloid Leukemia ,Life satisfaction ,Quality of life ,Allogeneic stem cell transplantation ,Oncology - Abstract
Background: Allogeneic stem cell transplantation (alloSCT) is the preferred option of postremission therapy for high-risk patients suffering from acute myeloid leukemia (AML). Therefore, monitoring life satisfaction (LS) of long-term survivors following alloSCT is becoming increasingly important for oncologists. The aim of the study was to evaluate individual survivor priority of various general and health-related domains of life and their satisfaction with these domains. Furthermore, we investigated the impact of general and health-related LS on resilience, anxiety, depression and quality of life in AML survivors following alloSCT. Methods: Forty-one AML survivors (median age at time of assessment = 49.0 years) who had undergone alloSCT (median time since transplantation = 3.1 years) were enrolled in the study. Psychosocial parameters were assessed using the following instruments: FLZM (Questions on Life Satisfaction), EORTC QLQ-C30, HADS (Hospital Anxiety and Depression Scale) and the RS-25 (Resilience Scale-25 items). Correlation analyses were computed to reveal the associations between the different questionnaires. Results: Independence from help or care, well-regulated living conditions and financial security contributed positively to LS, whereas being off work due to health-reasons and dissatisfaction with physical aspects were negatively associated to the subjective feelings of overall satisfaction. Moreover, a high quality of life was strongly positively correlated with LS (Spearman’s rho general LS: 0.643 and health-related LS: 0.726, both p
- Full Text
- View/download PDF
40. From Pandemic to Epidemic: Lessons Learned From COVID-19 Applied to Mpox Outbreak Response, Westchester County, Metropolitan New York.
- Author
-
Keller M, Hellman M, Hewlett D Jr, Chaturvedi V, Chen DS, Watson J, Huang A, Recchia R, Amler S, and Garrick R
- Subjects
- Humans, Pandemics prevention & control, New York epidemiology, Disease Outbreaks prevention & control, Mpox, Monkeypox, COVID-19 epidemiology, COVID-19 prevention & control
- Abstract
The COVID-19 pandemic vaccination infrastructure was redeployed to address the Mpox epidemic. The Westchester County Department of Health coordinated an effective vaccine distribution, tracking, and data collection process with community partners with real-time feedback of operational challenges and updated public health directives. Westchester County, which comprises 9% of the New York State population, administered 24% (6770 doses) of JYNNEOS (smallpox and monkeypox vaccine) across the state. Among first-dose recipients, 13% were Black and 25% were Hispanic, approaching countywide US Census race and ethnicity breakdowns. The operational template designed during COVID-19 can be readily redeployed for subsequent epidemics of even seemingly dissimilar infections like Mpox., Competing Interests: There are no conflicts of interest to report., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
41. Acute megakaryoblastic leukaemia shows high frequency of chromosome 1q aberrations and dismal outcome.
- Author
-
Pastore F, Gittinger H, Raab S, Tschuri S, Ksienzyk B, Konstandin NP, Schneider S, Rothenberg-Thurley M, Horny HP, Werner M, Sauerland MC, Amler S, Görlich D, Berdel WE, Wörmann B, Braess J, Hiddemann W, Tischer J, Herold T, Metzeler KH, and Spiekermann K
- Subjects
- Adult, Humans, Middle Aged, Retrospective Studies, Disease-Free Survival, Neoplasm Recurrence, Local genetics, Chromosome Aberrations, Prognosis, Chromosomes, Leukemia, Megakaryoblastic, Acute genetics, Leukemia, Megakaryoblastic, Acute therapy, Leukemia, Myeloid, Acute genetics, Hematopoietic Stem Cell Transplantation adverse effects
- Abstract
Acute megakaryoblastic leukaemia (AMKL) is associated with poor prognosis. Limited information is available on its cytogenetics, molecular genetics and clinical outcome. We performed genetic analyses, evaluated prognostic factors and the value of allogeneic haematopoietic stem cell transplantation (allo-HSCT) in a homogenous adult AMKL patient cohort. We retrospectively analysed 38 adult patients with AMKL (median age: 58 years, range: 21-80). Most received intensive treatment in AML Cooperative Group (AMLCG) trials between 2001 and 2016. Cytogenetic data showed an accumulation of adverse risk markers according to ELN 2017 and an unexpected high frequency of structural aberrations on chromosome arm 1q (33%). Most frequently, mutations occurred in TET2 (23%), TP53 (23%), JAK2 (19%), PTPN11 (19%) and RUNX1 (15%). Complete remission rate in 33 patients receiving intensive chemotherapy was 33% and median overall survival (OS) was 33 weeks (95% CI: 21-45). Patients undergoing allo-HSCT (n = 14) had a superior median OS (68 weeks; 95% CI: 11-126) and relapse-free survival (RFS) of 27 weeks (95% CI: 4-50), although cumulative incidence of relapse after allo-HSCT was high (62%). The prognosis of AMKL is determined by adverse genetic risk factors and therapy resistance. So far allo-HSCT is the only potentially curative treatment option in this dismal AML subgroup., (© 2023 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
42. Immunocompetent hamsters as a model for orthobunyavirus-induced neuroinvasion and neuropathology.
- Author
-
Groseth A, Gardner D, Meade-White K, Amler S, and Ebihara H
- Subjects
- Humans, Animals, Female, Cricetinae, Brain, Orthobunyavirus, Bunyamwera virus, Bunyaviridae Infections, Encephalitis
- Abstract
Background: Bunyavirus infections, including those caused by Bunyamwera serogroup orthobunyaviruses, represent a significant and yet likely still vastly underappreciated cause of mild to moderate human febrile infections. In severe cases, these infections can also cause neurological disease, particularly meningitis and encephalitis, and infection can even be fatal. However, with a few exceptions, information regarding the mechanisms underlying the neuroinvasion and neuropathogenesis of such infections is limited. This is due in part to a lack of animal models to facilitate such studies., Methodology/principal Findings: In an effort to develop an immunocompetent model of infection with Bunyamwera serogroup orthobunyaviruses, we infected 4-6-week-old female hamsters via either the intraperitoneal or subcutaneous route with 106 pfu/animal of Bunyamwera virus (BUNV), Batai virus or Ngari virus. Only BUNV infection resulted in clinical disease, which was characterized by weight loss, lethargy and neurological signs (i.e. tremor of the head or limbs, loss of righting reflex, "waltzing"). While symptoms were of similar severity for both routes, they occurred more frequently following subcutaneous inoculation. Consistent with these clinical signs, both antigen staining and histopathological abnormalities were found extensively throughout the brain., Conclusions/significance: The reported hamster model of BUNV infection provides a new tool for studying orthobunyavirus infection, and particularly neuroinvasion and the development of neuropathology. This model is particularly significant because it makes use of immunologically competent animals and relies on a subcutaneous inoculation route that more closely mimics the natural infection route for arboviruses, thereby providing a more authentic cellular and immunological context at the initial site of infection., Competing Interests: The authors have declared that no competing interests exist., (Copyright: This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.)
- Published
- 2023
- Full Text
- View/download PDF
43. SARS-CoV-2 in assisted living: Mortality and asymptomatic infection.
- Author
-
Montecalvo MA, Amler S, Cudjoe TKM, Smittle L, D'Ascanio A, Huang A, Recchia R, and Hewlett D
- Subjects
- Asymptomatic Infections, Humans, Infection Control, COVID-19, SARS-CoV-2
- Abstract
In response to a rapid rise in mortality within assisted living, facility-wide resident testing found 42% of 182 residents had SARS-CoV-2 infection; 68% of which were asymptomatic for 14 days before and after testing. Resident testing was a critical infection control measure needed to control transmission of SARS-CoV-2 infection., (Copyright © 2022. Published by Elsevier Inc.)
- Published
- 2022
- Full Text
- View/download PDF
44. Effect of Bone Morphogenetic Protein-2 in the Treatment of Long Bone Non-Unions.
- Author
-
Fuchs T, Stolberg-Stolberg J, Michel PA, Garcia P, Amler S, Wähnert D, and Raschke MJ
- Abstract
Background: Delayed fracture healing continues to cause significant patient morbidity and an economic burden to society. Biological stimulation of non-unions includes application of recombinant bone morphogenetic protein-2 (rhBMP-2). However, rhBMP-2 use continues to be a matter of controversy as literature shows scarce evidence for treatment effectiveness., Questions: The objective of this study was to evaluate the effectiveness of rhBMP-2 treatment on long bone non-unions measuring union rate and time to union. Furthermore, we assess risk factors for treatment failure., Methods and Patients: A total of 91 patients with non-unions of long bones were treated with rhBMP-2 ( n = 72) or standard care without BMP ( n = 19) at our institution. Patient characteristics, comorbidities, nicotine consumption, and complications were recorded. Bone healing was assessed by plane X-rays and clinical examination. Patients were followed up with for 24 months., Results: Overall, there was significantly faster bone healing after rhBMP-2 application compared to the no-BMP group ( p < 0.001; HR = 2.78; 95% CI 1.4-5.6). Union rates differed significantly between rhBMP-2 compared to the no-BMP group (89% vs. 47%; p < 0.001). At the humerus, there was neither a significantly higher union rate in the rhBMP-2 (83%) compared to the no-BMP group (50%) ( p = 0.26; n = 12) nor a faster bone healing with a median time of 9 months in both groups (HR = 2.01; 95% CI 0.49-8.61; p = 0.315). The 33 femora treated using rhBMP-2 healed significantly faster than 9 femora in the no-BMP group (HR = 2.93; 95% CI 1.00-8.4; p = 0.023) with significant differences in union rate with 85% and 44%, respectively ( p = 0.022). Regarding tibia non-unions, 25 out of 27 (93%) healed with a median of 9 months after rhBMP-2 application with no significant difference in the no-BMP group (33%) in time to union ( p = 0.097) but a significantly higher union rate ( p = 0.039). There was no effect of comorbidities, age, sex, soft tissue damage, or nicotine use on time to union, union rate, or secondary interventions., Conclusion: Consistent with the literature, overall, significantly higher union rates with reduced time to union were achieved after rhBMP-2 application. Femoral and tibial non-unions in particular seem to profit from rhBMP-2 application.
- Published
- 2021
- Full Text
- View/download PDF
45. Assessing the occurrence of the novel zoonotic variegated squirrel bornavirus 1 in captive squirrels in Germany -A prevalence study.
- Author
-
Allendorf V, Rubbenstroth D, Schlottau K, Hoffmann D, Frank C, Amler S, Beer M, Conraths FJ, and Homeier-Bachmann T
- Subjects
- Animals, Animals, Zoo, Bornaviridae genetics, Communicable Diseases, Emerging veterinary, Cross-Sectional Studies, Germany epidemiology, Phylogeny, Prevalence, RNA, Viral genetics, Rodent Diseases epidemiology, Zoonoses, Bornaviridae classification, Rodent Diseases virology, Sciuridae virology
- Abstract
The newly described zoonotic variegated squirrel bornavirus 1 (VSBV-1) in German squirrel holdings has been associated with the death of three private owners and one zoo animal caretaker (confirmed cases). Epidemiological investigations were severely impeded by the general lack of data on holdings of the putative reservoir hosts, the family Sciuridae. To fill this lack of data for detailed epidemiological investigations of the captive squirrel population, a register of private and zoological squirrel holdings was established. The findings show a broad variety of kept species and their frequency distribution. By contacting the different stakeholders via Web-based social groups and societies, information passed in both directions so that disease awareness could be raised and participants could be recruited for further studies. Cross-sectional studies revealed a prevalence of VSBV-1-positive subpopulations of 0% (95% CI 0%-6.2%) among private squirrel collections and 1.9% (95% CI: 0%-9.9%) among zoos in Germany. The approach presented here can be transferred to other populations of non-traditional pets, which may be equally difficult to monitor, in the case of an emerging zoonotic infectious disease., (© 2021 The Authors. Zoonoses and Public Health published by Wiley-VCH GmbH.)
- Published
- 2021
- Full Text
- View/download PDF
46. Neutralizing Antibody Responses in COVID-19 Convalescent Sera.
- Author
-
Lee WT, Girardin RC, Dupuis AP, Kulas KE, Payne AF, Wong SJ, Arinsburg S, Nguyen FT, Mendu DR, Firpo-Betancourt A, Jhang J, Wajnberg A, Krammer F, Cordon-Cardo C, Amler S, Montecalvo M, Hutton B, Taylor J, and McDonough KA
- Subjects
- Enzyme-Linked Immunosorbent Assay, Humans, Immunization, Passive, COVID-19 Serotherapy, Antibodies, Neutralizing blood, Antibodies, Viral blood, COVID-19 therapy, Neutralization Tests
- Abstract
Passive transfer of antibodies from COVID-19 convalescent patients is being used as an experimental treatment for eligible patients with SARS-CoV-2 infections. The United States Food and Drug Administration's (FDA) guidelines for convalescent plasma initially recommended target antibody titers of 160. We evaluated SARS-CoV-2 neutralizing antibodies in sera from recovered COVID-19 patients using plaque reduction neutralization tests (PRNT) at moderate (PRNT50) and high (PRNT90) stringency thresholds. We found that neutralizing activity significantly increased with time post symptom onset (PSO), reaching a peak at 31-35 days PSO. At this point, the number of sera having neutralizing titers of at least 160 was approximately 93% (PRNT50) and approximately 54% (PRNT90). Sera with high SARS-CoV-2 antibody levels (>960 enzyme-linked immunosorbent assay titers) showed maximal activity, but not all high-titer sera contained neutralizing antibody at FDA recommended levels, particularly at high stringency. These results underscore the value of serum characterization for neutralization activity., (© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.)
- Published
- 2021
- Full Text
- View/download PDF
47. Author Correction: The potential role of scavengers in spreading African swine fever among wild boar.
- Author
-
Probst C, Gethmann J, Amler S, Globig A, Knoll B, and Conraths FJ
- Abstract
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
- Published
- 2020
- Full Text
- View/download PDF
48. Modulation of lethal HPAIV H5N8 clade 2.3.4.4B infection in AIV pre-exposed mallards.
- Author
-
Koethe S, Ulrich L, Ulrich R, Amler S, Graaf A, Harder TC, Grund C, Mettenleiter TC, Conraths FJ, Beer M, and Globig A
- Subjects
- Animals, Antibodies, Viral blood, Ducks virology, Influenza A Virus, H5N8 Subtype genetics, Influenza A Virus, H5N8 Subtype pathogenicity, Influenza in Birds blood, Influenza in Birds mortality, Liver virology, Poultry Diseases blood, Poultry Diseases mortality, Virulence, Virus Shedding, Influenza A Virus, H5N8 Subtype physiology, Influenza in Birds virology, Poultry Diseases virology
- Abstract
In 2016/2017, a severe epidemic of HPAIV H5N8 clade 2.3.4.4 group B (H5N8B) affected Europe. To analyse the role of mallards in the spatiotemporal dynamics of global HPAIV H5N8B dispersal, mallards ( Anas platyrhynchos ), naturally exposed to various AIV and therefore seropositive, were challenged with H5N8B. All experiments were controlled by infection and co-housing of seronegative juvenile Pekin ducklings. All ducks that survived the first infection were re-challenged 21 dpi with the homologous H5N8B strain. After the first H5N8B infection, seropositive mallards showed only mild clinical symptoms. Moderate to low viral shedding, occurring particularly from the oropharynx and lasting for 7 days maximum, led to severe clinical disease of all contact ducklings. All challenged seronegative Pekin ducks and contact ducklings died or had to be euthanized. H5-specific antibodies were detected in surviving birds within 2 weeks. Virus and viral RNA could be isolated from several water samples until 6 and 9 dpi, respectively. Conversely, upon re-infection with homologous H5N8B neither inoculated nor contact ducklings showed any clinical symptoms, nor was an antibody titer increase of seropositive mallards or any seroconversion of contact ducklings observed. Mallard ducks naturally pre-exposed to LPAIV can play a role as a clinically unsuspicious virus reservoir for H5N8B effective in virus transmission. Mallards with homologous immunity did not contribute to virus transmission.
- Published
- 2020
- Full Text
- View/download PDF
49. High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008.
- Author
-
Dirksen U, Brennan B, Le Deley MC, Cozic N, van den Berg H, Bhadri V, Brichard B, Claude L, Craft A, Amler S, Gaspar N, Gelderblom H, Goldsby R, Gorlick R, Grier HE, Guinbretiere JM, Hauser P, Hjorth L, Janeway K, Juergens H, Judson I, Krailo M, Kruseova J, Kuehne T, Ladenstein R, Lervat C, Lessnick SL, Lewis I, Linassier C, Marec-Berard P, Marina N, Morland B, Pacquement H, Paulussen M, Randall RL, Ranft A, Le Teuff G, Wheatley K, Whelan J, Womer R, Oberlin O, and Hawkins DS
- Subjects
- Adolescent, Adult, Antineoplastic Combined Chemotherapy Protocols adverse effects, Bone Neoplasms mortality, Bone Neoplasms pathology, Child, Child, Preschool, Disease Progression, Europe, Female, Humans, Infant, Lung Neoplasms mortality, Lung Neoplasms secondary, Male, Middle Aged, Neoplasm Recurrence, Local, Pneumonectomy, Progression-Free Survival, Radiotherapy, Adjuvant, Risk Assessment, Risk Factors, Sarcoma, Ewing mortality, Sarcoma, Ewing secondary, Time Factors, Transplantation, Autologous, Young Adult, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Bone Neoplasms therapy, Hematopoietic Stem Cell Transplantation adverse effects, Hematopoietic Stem Cell Transplantation mortality, Lung Neoplasms therapy, Neoadjuvant Therapy adverse effects, Neoadjuvant Therapy mortality, Sarcoma, Ewing therapy
- Abstract
Purpose: The R2Pulm trial was conducted to evaluate the effect of busulfan-melphalan high-dose chemotherapy with autologous stem-cell rescue (BuMel) without whole-lung irradiation (WLI) on event-free survival (main end point) and overall survival, compared with standard chemotherapy with WLI in Ewing sarcoma (ES) presenting with pulmonary and/or pleural metastases., Methods: From 2000 to 2015, we enrolled patients younger than 50 years of age with newly diagnosed ES and with only pulmonary or pleural metastases. Patients received chemotherapy with six courses of vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) and one course of vincristine, dactinomycin, and ifosfamide (VAI) before either BuMel or seven courses of VAI and WLI (VAI plus WLI) by randomized assignment. The analysis was conducted as intention to treat. The estimates of the hazard ratio (HR), 95% CI, and P value were corrected for the three previous interim analyses by the inverse normal method., Results: Of 543 potentially eligible patients, 287 were randomly assigned to VAI plus WLI (n = 143) or BuMel (n = 144). Selected patients requiring radiotherapy to an axial primary site were excluded from randomization to avoid excess organ toxicity from interaction between radiotherapy and busulfan. Median follow-up was 8.1 years. We did not observe any significant difference in survival outcomes between treatment groups. Event-free survival was 50.6% versus 56.6% at 3 years and 43.1% versus 52.9% at 8 years, for VAI plus WLI and BuMel patients, respectively, resulting in an HR of 0.79 (95% CI, 0.56 to 1.10; P = .16). For overall survival, the HR was 1.00 (95% CI, 0.70 to 1.44; P = .99). Four patients died as a result of BuMel-related toxicity, and none died after VAI plus WLI. Significantly more patients in the BuMel arm experienced severe acute toxicities than in the VAI plus WLI arm., Conclusion: In ES with pulmonary or pleural metastases, there is no clear benefit from BuMel compared with conventional VAI plus WLI.
- Published
- 2019
- Full Text
- View/download PDF
50. The potential role of scavengers in spreading African swine fever among wild boar.
- Author
-
Probst C, Gethmann J, Amler S, Globig A, Knoll B, and Conraths FJ
- Subjects
- African Swine Fever epidemiology, African Swine Fever virology, African Swine Fever Virus pathogenicity, Animals, Crows virology, Falconiformes virology, Female, Foxes virology, Germany epidemiology, Male, Raccoon Dogs virology, Risk Factors, Seasons, Swine, Time Factors, African Swine Fever transmission, African Swine Fever Virus isolation & purification, Animals, Wild virology, Carnivory, Sus scrofa virology
- Abstract
Understanding the transmission patterns of African swine fever (ASF) among wild boar (Sus scrofa) is an issue of major interest, especially in the wake of the current ASF epidemic. Given the high stability of ASF-virus, there is concern about scavengers spreading infectious carcass material in the environment. Here, we describe scavenging activities on 32 wild boar carcasses in their natural habitat in Germany. Using digital cameras, we detected 22 vertebrates at the study sites, thereof two mammal and three bird species scavenging. The most frequently detected species was the raccoon dog Nyctereutes procyonoides (44% of all visits). Raccoon dogs, red foxes (Vulpes vulpes), and buzzards (Buteo buteo) scavenged in the warm and the cold season, while ravens (Corvus corax) and white-tailed eagles (Haliaeetus albicilla) scavenged only in the cold season. In summer, however, insects removed most of the carcass biomass. Although most of the material was consumed on the spot, foxes, raccoon dogs and ravens left the study sites in rare cases with a small piece of meat in their mouths or beaks. We conclude that scavengers represent a minor risk factor for spreading ASF, but may contribute to reducing local virus persistence by metabolizing infected carcasses.
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.